ArticleFrontiers in pediatrics2025
Effect of human serum albumin on clinical outcomes in pediatric patients undergoing gastrointestinal surgery.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the effectiveness of administering 20% human serum albumin (HSA) on short-term clinical outcomes in pediatric patients undergoing enteric anastomosis, with a specific focus on postoperative hospital stay (PHS), postoperative fasting duration (PFD), and the incidence of postoperative complications (PCs). Methods: This was a single-center, retrospective cohort study. Patients aged between 1 month and 18 years who underwent simple intestinal anastomosis were included. Comprehensive data, including patient demographics, prescribed medications, laboratory test results, and surgical records, were meticulously extracted from electronic patient dossiers. The primary endpoint was PHS. The second endpoint included PFD and PCs. Since this was a retrospective cohort study, we used propensity score matching (PSM) to balance different variables. The efficacy of 20% HSA on clinical outcomes was assessed by univariate and multivariate logistic regression analyses. Results: Among a cohort of 242 patients, 67 (27.69%) were administered 20% HSA for over 2 days during the early postoperative stage. A dose-related pattern of HSA efficacy on clinical outcomes was observed in the PSM cohort. After adjustment, HSA overuse was identified as an independent risk factor for prolonged PHS and a higher complication incidence, with odds ratios of 6.56 [95% confidence interval (CI): 2.12-20.32] and 5.14 (95% CI: 1.21-21.83), respectively. Conclusions: Overuse of 20% HSA in the early postoperative stage does not contribute to improved clinical outcomes in pediatric patients undergoing gastrointestinal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.